890 related articles for article (PubMed ID: 9881076)
21. Chemotherapy of Hodgkin's disease.
Carde P
Nouv Rev Fr Hematol (1978); 1990; 32(2):169-73. PubMed ID: 1696000
[TBL] [Abstract][Full Text] [Related]
22. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL
Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487
[TBL] [Abstract][Full Text] [Related]
23. [The chemotherapeutic treatment of advanced Hodgkin's disease].
Epelbaum R; Haim N; Ben-Shahar M; Valtuch I; Faraggi D; Sharabi-Nov A; Ben-Arie Y; Cohen Y
Harefuah; 2001 Apr; 140(4):311-5, 367. PubMed ID: 11303395
[TBL] [Abstract][Full Text] [Related]
24. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
[TBL] [Abstract][Full Text] [Related]
25. [Recurrence of Hodgkin's disease after advanced primary stages. German Hodgkin's Study Group].
Fuchs R; Löffler M; Pfreundschuh M; Dölken G; Gerhartz H; Hagen-Aukamp U; Hiller E; Petsch S; Pflüger KH; Rühl U
Med Klin (Munich); 1992 Nov; 87(11):555-62. PubMed ID: 1281905
[TBL] [Abstract][Full Text] [Related]
26. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
27. Combination chemotherapy with alternating MOPP-ABVD in advanced Hodgkin's disease.
Brusamolino E; Lazzarino M; Morra E; Inverardi D; Merante S; Castelli G; Canevari A; Dornini G; Bernasconi C
Haematologica; 1989; 74(2):173-9. PubMed ID: 2473013
[TBL] [Abstract][Full Text] [Related]
28. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
[TBL] [Abstract][Full Text] [Related]
29. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
[TBL] [Abstract][Full Text] [Related]
30. What is the treatment of choice for advanced-stage Hodgkin's lymphoma: ABVD, Stanford V, or BEACOPP?
Hehn ST; Miller TP
Curr Hematol Rep; 2004 Jan; 3(1):17-26. PubMed ID: 14695845
[TBL] [Abstract][Full Text] [Related]
31. Prognosis of bulky Hodgkin's disease treated with chemotherapy alone or combined with radiotherapy.
Bonadonna G; Valagussa P; Santoro A
Cancer Surv; 1985; 4(2):439-58. PubMed ID: 2430700
[TBL] [Abstract][Full Text] [Related]
32. Should MOPP-ABVD alone be standard for childhood Hodgkin's?
Constine LS
J Clin Oncol; 1998 Mar; 16(3):1235. PubMed ID: 9508214
[No Abstract] [Full Text] [Related]
33. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
[TBL] [Abstract][Full Text] [Related]
34. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
35. Comparison of MOPP/MOPP +/- RT vs. MOPp/ABVD +/- RT in poor prognosis Hodgkin's disease. Long-term results.
Comella P; Abate G; Fiore M; Di Finizio G; Frezza P; Scoppa G; Anania C; Coucourde F; Zarrilli D
J Chemother; 1989 Jul; 1(4 Suppl):1254-6. PubMed ID: 16312855
[No Abstract] [Full Text] [Related]
36. [Treatment of Hodgkin's disease in children with chemotherapy and low-dose radiation].
Leverger G; Oberlin O; Schaison G; Lemerle J
Nouv Rev Fr Hematol (1978); 1987; 29(1):83-5. PubMed ID: 2438648
[TBL] [Abstract][Full Text] [Related]
37. Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD?
Canellos GP
Leukemia; 1996 Jun; 10 Suppl 2():s68. PubMed ID: 8649055
[No Abstract] [Full Text] [Related]
38. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program.
Klimo P; Connors JM
Semin Hematol; 1988 Apr; 25(2 Suppl 2):34-40. PubMed ID: 2456621
[TBL] [Abstract][Full Text] [Related]
39. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe.
Harker WG; Kushlan P; Rosenberg SA
Ann Intern Med; 1984 Oct; 101(4):440-6. PubMed ID: 6206757
[TBL] [Abstract][Full Text] [Related]
40. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.
Santoro A; Viviani S; Villarreal CJ; Bonfante V; Delfino A; Valagussa P; Bonadonna G
Cancer Treat Rep; 1986 Mar; 70(3):343-8. PubMed ID: 2420444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]